Touma Z - Search Results

1

SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation.

Touma Z, Urowitz MB, Ibañez D, Gladman DD. Touma Z, et al. Lupus. 2011 Jan;20(1):67-70. doi: 10.1177/0961203310385163. Lupus. 2011. PMID: 21233149

2

Longitudinal myelitis in patient with systemic lupus erythematosus, homozygous prothrombin G20210A and heterozygous MTHFR 677T.

Touma Z, Atweh SF, Kibbi L, Arayssi T. Touma Z, et al. Lupus. 2007;16(7):517-20. doi: 10.1177/0961203307077830. Lupus. 2007. PMID: 17670851

3

SLEDAI-2K for a 30-day window.

Touma Z, Urowitz MB, Gladman DD. Touma Z, et al. Lupus. 2010 Jan;19(1):49-51. doi: 10.1177/0961203309346505. Epub 2009 Nov 12. Lupus. 2010. PMID: 19910390

4

Burden of autoantibodies and association with disease activity and damage in systemic lupus erythematosus.

Touma Z, Gladman DD, Tulloch-Reid D, Toloza SM, Ibañez D, Fortin PR, Urowitz MB. Touma Z, et al. Clin Exp Rheumatol. 2010 Jul-Aug;28(4):525-31. Epub 2010 Aug 30. Clin Exp Rheumatol. 2010. PMID: 20659409

5

Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis.

Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Touma Z, et al. J Rheumatol. 2011 Jan;38(1):69-78. doi: 10.3899/jrheum.100130. Epub 2010 Oct 15. J Rheumatol. 2011. PMID: 20952473 Review.

6

Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time.

Ibañez D, Gladman DD, Touma Z, Nikpour M, Urowitz MB. Ibañez D, et al. Among authors: touma z. J Rheumatol. 2011 Jan;38(1):60-3. doi: 10.3899/jrheum.100575. Epub 2010 Nov 15. J Rheumatol. 2011. PMID: 21078718

7

Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50.

Touma Z, Gladman DD, Ibañez D, Urowitz MB. Touma Z, et al. J Rheumatol. 2011 Feb;38(2):275-84. doi: 10.3899/jrheum.100724. Epub 2010 Dec 1. J Rheumatol. 2011. PMID: 21123323

8

Systemic lupus erythematosus disease activity index 2000 responder index-50: a reliable index for measuring improvement in disease activity.

Touma Z, Urowitz MB, Fortin PR, Landolt C, Toloza SM, Riddell C, Chandran V, Eder L, Ghanem A, Ziouzina O, Taghavi-Zadeh S, Ibañez D, Gladman DD. Touma Z, et al. J Rheumatol. 2011 May;38(5):868-73. doi: 10.3899/jrheum.101080. Epub 2011 Feb 15. J Rheumatol. 2011. PMID: 21324961

9

Cross-cultural adaptation and validation of Behçet's disease quality of life questionnaire.

Touma Z, Ghandour L, Sibai A, Puzantian H, Hamdan A, Hamdan O, Menassa J, Uthman I, Arayssi T. Touma Z, et al. BMC Med Res Methodol. 2011 Apr 20;11:52. doi: 10.1186/1471-2288-11-52. BMC Med Res Methodol. 2011. PMID: 21507231 Free PMC article.

10

Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?

Touma Z, Gladman DD, Ibañez D, Urowitz MB. Touma Z, et al. J Rheumatol. 2011 Sep;38(9):1898-905. doi: 10.3899/jrheum.110007. Epub 2011 Jul 1. J Rheumatol. 2011. PMID: 21724700

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results